SKG0106

· Skyline Therapeutics (US) Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for SKG0106, covering 2024-04-30 to 2025-01-09. Get the full timeline:

Most recent: Clinical Trial Update: Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD) [Phase 1, Phase 2]

See pricing